ABSI241220P1000
- 0.00
- 0.000.00%
Absci Corp Newsroom
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7
Express News | HC Wainwright & Co. Reiterates Buy on Absci, Maintains $7 Price Target
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating
Express News | Absci Shares Are Trading Higher After the Company Highlighted Progress and Updates Across Its Proprietary Pipeline and Leading AI Platform on 2024 R&D Day. Its Drug Candidate Was Selected for ABS-201, an Anti-PRLR Antibody in Development for...
Absci Corporation Advances Internal Pipeline With New Drug Candidate ABS-201 for Androgenic Alopecia and Breakthroughs in AI-Designed Antibodies
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Absci Up Nearly 22%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
Absci Corporation (NASDAQ:ABSI) Is Favoured by Institutional Owners Who Hold 56% of the Company
JonesTrading Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $9
Absci a New Buy at Jones on AI Platform to Design Antibodies
JonesTrading Initiates Absci at Buy With $9 Price Target
Absci Price Target Maintained With a $10.00/Share by Guggenheim
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care
Stifel Maintains Absci Corp(ABSI.US) With Hold Rating, Maintains Target Price $6
Absci Analyst Ratings
Scotiabank Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $13